All In Biotech

Drug Trial Radar · NCT07819799

Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Jul 15, 2028

Study completion Jul 15, 2028

Sponsor

Lead sponsor
Attovia Therapeutics IncIndustry
Sponsor type
Industry
First posted
Sep 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1091? How long does ATTO-1091 stay in the body after dosing? Researchers will compare ATTO-1091 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1091 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • ATTO-1091Drug

    ATTO-1091

  • PlaceboDrug

    Placebo preparation to match ATTO-1091 dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: 0-169 Days for SAD; 0-204 Days for MAD in HV; 0-141 Days for MAD in UC
  2. Incidence of laboratory abnormalitiesTime frame: 0-169 Days for SAD; 0-204 Days for MAD in HV; 0-141 Days for MAD in UC
  3. Incidence of ECG abnormalitiesTime frame: 0-169 Days for SAD; 0-204 Days for MAD in HV; 0-141 Days for MAD in UC
  4. Incidence of vital sign abnormalitiesTime frame: 0-169 Days for SAD; 0-204 Days for MAD in HV; 0-141 Days for MAD in UC

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.